Compare SLNG & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | MNOV |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.2M | 66.9M |
| IPO Year | 2019 | 2004 |
| Metric | SLNG | MNOV |
|---|---|---|
| Price | $4.10 | $1.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.00 | $7.50 |
| AVG Volume (30 Days) | ★ 72.4K | 56.5K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2400.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,245,000.00 | $2,360,807.00 |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $14.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $3.21 | $1.13 |
| 52 Week High | $6.36 | $1.96 |
| Indicator | SLNG | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 46.76 |
| Support Level | $4.36 | $1.21 |
| Resistance Level | $5.13 | $1.43 |
| Average True Range (ATR) | 0.46 | 0.06 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 76.74 | 26.41 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.